Improvements in hepatic steatosis, obesity, and insulin resistance in adults with nonalcoholic fatty liver disease after the primary obesity surgery endoluminal 2.0 procedure.

Autor:	AlKhatry M; Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates., Rapaka B; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Maselli DB; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Abboud DM; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Brunaldi VO; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.; Gastroenterology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil., Mahmoud T; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Ghazi R; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Abdul Razzak F; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Gala K; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Joudah I; Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates., Housen F; Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates., Al Qadi S; Department of Gastroenterology, Obaidulla Hospital, Ras Al Khaimah, Emirates Health Services, Ministry of Health, United Arab Emirates., Vargas EJ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Storm AC; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States., Abu Dayyeh BK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
Jazyk:	angličtina
Zdroj:	Endoscopy [Endoscopy] 2023 Nov; Vol. 55 (11), pp. 1028-1034. Date of Electronic Publication: 2023 Jun 26.
DOI:	10.1055/a-2117-6274
Abstrakt:	Background: The primary obesity surgery endoluminal 2.0 (POSE 2.0) procedure involves full-thickness gastric body plications to narrow the stomach using durable suture anchor pairs. We evaluated POSE 2.0 as a treatment strategy for nonalcoholic fatty liver disease (NAFLD) in patients with obesity. Methods: Adults with obesity and NAFLD were prospectively allocated based on their preference to undergo POSE 2.0 with lifestyle modification or lifestyle modification alone (control). Primary end points were improvement in controlled attenuation parameter (CAP) and resolution of hepatic steatosis at 12 months. Secondary end points included %total body weight loss (%TBWL), change in serum measures of hepatic steatosis and insulin resistance, and procedure safety. Results: 42 adult patients were included (20 in the POSE 2.0 arm and 22 in the control arm). At 12 months, POSE 2.0 significantly improved CAP, whereas lifestyle modification alone did not ( P  < 0.001 for POSE 2.0; P  = 0.24 for control). Similarly, both resolution of steatosis and %TBWL were significantly higher with POSE 2.0 than with control at 12 months. Compared with controls, POSE 2.0 significantly improved liver enzymes, hepatic steatosis index, and aspartate aminotransferase to platelet ratio at 12 months. There were no serious adverse events. CONCLUSION : POSE 2.0 was effective for NAFLD in patients with obesity, with good durability and safety profile. Competing Interests: B.K. Abu Dayyeh reports consultant roles with Endogenex, Endo-TAGSS, Metamodix, and BFKW; consultant and grant/research support from USGI, Apollo Endosurgery, Spatz Medical, Cairn Diagnostics, Aspire Bariatrics, Boston Scientific; Speaker roles with Olympus, Johnson and Johnson; and speaker and grant/research support from Medtronic, Endogastric solutions. A.C. Storm reports institutional research grants from Boston Scientific, Enterasense, Endogenex; consulting fees from Olympus; consulting fees and research grants from Endo-TAGSS, and Apollo Endosurgery; and participation in Data Safety Monitoring Board with GI Dynamics, and ERBE. M. AlKhatry, B. Rapaka, D.B. Maselli, D.M. Abboud, V.O. Brunaldi, T. Mahmoud, R. Ghazi, F. Abdul Razzak, K. Gala, I. Joudah, F. Housen, S. Al Qadi, and E.J. Vargas declare that they have no conflict of interest. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu